Elinogrel antiplatelets drug

Description Results NMA

major bleeding NaN [NaN; NaN]

non fatla stroke ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34)

vs.

placebo (n=36)

5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI

double blind

Parallel groups

Sample size: 34/36

Primary endpoint: TIMI and ST resolution

FU duration: 30-37 days

phase IIb (dose-escalation study)

major bleeding NaN [NaN; NaN]

non fatla stroke ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34)

vs.

placebo (n=36)

5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI

double blind

Parallel groups

Sample size: 34/36

Primary endpoint: TIMI and ST resolution

FU duration: 30-37 days

phase IIb (dose-escalation study)

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: